Aggressive Antipyretics for Fever Reduction in CNS Malaria

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

256 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-07

Study Completion Date

2022-12-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will examine whether prophylactic and scheduled treatment with acetaminophen and ibuprofen can decrease the maximum temperature experienced during the acute illness in children with CNS malaria.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Fever Due to Malaria With Ibuprofen

NCT00167713

Fever

COMPLETED PHASE4

An MRI Ancillary Study of a Malaria Fever Investigation

NCT05746819

Brain Injuries Malaria MRI Imaging +3 more

COMPLETED

The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau

NCT00137566

Malaria Falciparum

UNKNOWN PHASE4

Can Treatment of Malaria be Restricted to Parasitologically Confirmed Malaria?

NCT00913146

Malaria

COMPLETED

Innovative Public-private Partnership to Target Subsidized Antimalarials in the Retail Sector

NCT02199977

Fever Malaria

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Despite ongoing eradication efforts, malaria remains a major public health challenge in Africa where annually, \~250,000 children with malaria experience a neurologic injury with subsequent neurodisability. In other central nervous system (CNS) disorders, fever is a recognized cause of worsening secondary neurologic injury and ex-tensive efforts are made to avoid hyperthermia or induce hypothermia for neuroprotection. Evidence indicates that among children with CNS malaria a higher temperature during the acute illness is a risk factor for post-infectious neurologic sequelae. As such, aggressive antipyretic therapy may be warranted, at least among children with complicated malaria who are at substantial risk of brain injury. Previous clinical trials conducted primarily in children with uncomplicated malaria and using only a single antipyretic medication have shown limited benefits in terms of fever reduction; however, no studies to date have examined malaria fever management using dual therapies. Enthusiasm for aggressive fever reduction measures among clinicians caring for children with malaria has been curbed by in vitro findings that malaria parasite replication slows at higher temperatures and a single clinical trial in which peripheral parasite clearance was slower in children receiving treatment for fever. However, the relationship between temperature and malaria parasite behavior is complex. Additional in vitro data suggest that at febrile temperatures uninfected red blood cells (RBCs) are more likely to adhere to infected RBCs, worsening the process of sequestration, increasing the parasite burden obstructing microvascular cerebral blood flow, and perhaps contributing to ongoing immunopathogenesis in CNS malaria. In this exploratory clinical trial of aggressive antipyretic therapy, children hospitalized with CNS malaria will be randomized to usual care (acetaminophen every 6 hours for a temperature ≥ 38.5ºC) vs. prophylactic acetaminophen and ibuprofen every 6 hours for 72 hours. This proof-of-concept study will determine whether aggressive antipyretic therapy results in a lower mean maximum temperature relative to usual care. Serial quantitative levels of histidine rich protein 2 (HRP2), a P. falciparum-specific protein that facilitates estimates of whole body parasite burden and CNS parasite sequestration, will also be collected to clarify the relationship between antipyretic use and in vivo parasite behavior. Findings from this study will determine whether a Phase III clinical trial of aggressive antipyretics for neuroprotection in pediatric CNS malaria should be undertaken. This study will take place in Zambia and Malawi, where prior NIH-funded collaborations have assisted in developing the substantial infrastructure needed to undertake a clinical trial of this nature.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria Seizures Coma Parasitemia Hyperpyrexia Fever

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aggressive Antipyretics

regardless of temperature, children allocated to this arm will receive acetaminophen (30 milligrams (mg)/ kilogram (kg) load then 15mg/kg Q6 hours) and ibuprofen (10mg/kg Q 6 hours) for 72 hours. Pediatric syrup formulations of both agents will be administered orally or via nasogastric tube. For temperatures over 38.5 degrees Celsius, placebo will be added and if the fever persists, a cooling fan will be added.

Group Type EXPERIMENTAL

Acetaminophen

Intervention Type DRUG

30 mg/kg load then 15mg/kg Q6 hours for the Aggressive Antipyretic Arm

Acetaminophen is also given to children in the placebo arm when they have a fever over 38.5 degrees Celsius during scheduled clinical assessments

Ibuprofen

Intervention Type DRUG

10 mg/kg Q6 hours for the Aggressive Antipyretic Arm

Usual Care

will receive placebo for acetaminophen and placebo for ibuprofen. If they have a temperature over 38.5 degrees Celsius, they will receive acetaminophen (15mg/kg, Q6 hours), as needed. If the fever persists, a cooling fan will be added.

Group Type PLACEBO_COMPARATOR

placebo for acetaminophen

Intervention Type DRUG

placebo for acetaminophen for children in the Usual Care arm

For children in the Aggressive Antipyretic Arm, when they have a temperature over 38.5 degrees Celsius they are treated with a placebo

placebo for ibuprofen

Intervention Type DRUG

placebo for ibuprofen

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acetaminophen

30 mg/kg load then 15mg/kg Q6 hours for the Aggressive Antipyretic Arm

Acetaminophen is also given to children in the placebo arm when they have a fever over 38.5 degrees Celsius during scheduled clinical assessments

Intervention Type DRUG

Ibuprofen

10 mg/kg Q6 hours for the Aggressive Antipyretic Arm

Intervention Type DRUG

placebo for acetaminophen

placebo for acetaminophen for children in the Usual Care arm

For children in the Aggressive Antipyretic Arm, when they have a temperature over 38.5 degrees Celsius they are treated with a placebo

Intervention Type DRUG

placebo for ibuprofen

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Paracetamol Brufen Placebo Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Evidence of Plasmodium falciparum malaria infection by peripheral blood smear or rapid diagnostic test
* Central nervous system (CNS) symptoms associated with malaria. CEREBRAL MALARIA (CM): Impaired consciousness with a Blantyre Coma Score (BCS)(73) ≤2 in children under 5 years or a Glasgow Coma score (GCS) ≤10 in children ≥5 years OR CNS MALARIA: Complicated seizure(s), meaning prolonged (\>15 minutes), focal or multiple; or impaired consciousness or other evidence of impaired consciousness (confusion, delirium) without frank coma (BCS\>2, GCS =11-14)

Exclusion Criteria

* Circulatory failure (cold extremities, capillary refill \> 3 seconds, sunken eyes, ↓ skin turgor)
* Vomiting in the past 2 hours
* Serum creatinine (Cr) \> 1.2 mg/dL
* A history of liver disease
* Jaundice or a total bilirubin of \>3.0mg/dL
* A history of gastric ulcers or gastrointestinal bleeding
* A history of thrombocytopenia or other primary hematologic disorder
* Petechiae or other clinical indications of bleeding abnormalities
* A known allergy to ibuprofen, acetaminophen, aspirin or any non-steroidal medication
* Any contraindication for nasogastric tube (NGT) placement and/or delivery of enteral medications

Minimum Eligible Age

2 Years

Maximum Eligible Age

11 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No